340B program stakeholders are still digesting drug manufacturers AstraZeneca, Eli Lilly and Co., and Sanofi’s Jan. 12 lawsuits to block federal sanctions over their decisions to stop or impose conditions on 340B discounts on drugs dispensed by contract pharmacies.
The three drug manufacturers sued the U.S. Health and Human Services Department (HHS), the Health Resources and Services Administration (HRSA), and top HHS and HRSA executives the day before HRSA began accepting 340B covered entity claims against drug companies under HRSA’s new 340B program administrative dispute resolution (ADR) system.
340B program stakeholders are still digesting drug manufacturers AstraZeneca, Eli Lilly and Co., and Sanofi’s Jan. 12 lawsuits to block federal sanctions over their decisions to stop or impose conditions on 340B discounts on drugs dispensed by contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.